Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Chief Medical Officer | June 11, 2021 | June 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-06-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-06-11 · Exercise / conversion · Acquired 1,000 · Balance 1,000 Row 2 · 2021-06-11 · Sale · Disposed 653 · Balance 347 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $51.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Row 3 · 2021-06-11 · Sale · Disposed 347 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.21 inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2029-09-18 | Direct | 98,211 |
Reported balance
After 2021-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-11 · Exercise / conversion · Disposed 1,000 · Balance 98,211 F4: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $51.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.21 inclusive.
F4: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2021 Filed Jun 15, 2021 17:01 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-040648 · doc4.xml · derivative · entry 4 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,211 Underlying: Common Stock · 1,000 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:01 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 347 | $51.95 | $18,026.65 |
DisclosureSEC source: 0001209191-21-040648 · doc4.xml · nonDerivative · entry 3 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.21 inclusive. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:01 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 653 | $50.48 | $32,963.44 |
DisclosureSEC source: 0001209191-21-040648 · doc4.xml · nonDerivative · entry 2 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.15 to $51.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:01 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,000 | $0.48 | $480.00 |
DisclosureSEC source: 0001209191-21-040648 · doc4.xml · nonDerivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-032361 · doc4.xml · derivative · entry 3 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,211 Underlying: Common Stock · 1,000 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,000 | $50.15 | $50,150.00 |
DisclosureSEC source: 0001209191-21-032361 · doc4.xml · nonDerivative · entry 2 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,000 | $0.48 | $480.00 |
DisclosureSEC source: 0001209191-21-032361 · doc4.xml · nonDerivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-026669 · doc4.xml · derivative · entry 5 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,211 Underlying: Common Stock · 1,000 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 233 | $61.23 | $14,266.59 |
DisclosureSEC source: 0001209191-21-026669 · doc4.xml · nonDerivative · entry 4 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.08 to $61.40 inclusive. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 367 | $60.01 | $22,023.67 |
DisclosureSEC source: 0001209191-21-026669 · doc4.xml · nonDerivative · entry 3 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.44 inclusive. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 400 | $59.09 | $23,636.00 |
DisclosureSEC source: 0001209191-21-026669 · doc4.xml · nonDerivative · entry 2 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.58 to $59.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:46 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,000 | $0.48 | $480.00 |
DisclosureSEC source: 0001209191-21-026669 · doc4.xml · nonDerivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:45 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-020483 · doc4.xml · derivative · entry 4 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,211 Underlying: Common Stock · 1,000 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:45 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 605 | $64.86 | $39,240.30 |
DisclosureSEC source: 0001209191-21-020483 · doc4.xml · nonDerivative · entry 3 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.59 to $65.48 inclusive. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:45 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 395 | $64.09 | $25,315.55 |
DisclosureSEC source: 0001209191-21-020483 · doc4.xml · nonDerivative · entry 2 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.535 to $64.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:45 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,000 | $0.48 | $480.00 |
DisclosureSEC source: 0001209191-21-020483 · doc4.xml · nonDerivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · derivative · entry 7 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,211 Underlying: Common Stock · 1,000 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2 | $68.05 | $136.10 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 6 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 295 | $66.19 | $19,526.05 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 5 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.69 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 216 | $65.35 | $14,115.60 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 4 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.855 to $65.73 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 312 | $64.17 | $20,021.04 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 3 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.775 to $64.535 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 175 | $63.10 | $11,042.50 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 2 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:49 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,000 | $0.48 | $480.00 |
DisclosureSEC source: 0001209191-21-010882 · doc4.xml · nonDerivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2021 Filed Jan 12, 2021 17:23 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 42,250 | $0.00 Strike: $70.93 | $0.00 |
DisclosureSEC source: 0001209191-21-003273 · doc4.xml · derivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,250 Underlying: Common Stock · 42,250 shares Expires 2031-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 21:01 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 18,430 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023989 · doc4.xml · derivative · entry 1 Ordonez Claudia · CIK 0001808290 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,430 Underlying: Common Stock · 18,430 shares Expires 2030-04-06 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on March 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.